Hatchtech concludes treatment in head lice drug Phase 2b trial – Pharmaceutical Business Review
Thursday, September 1st, 2011Hatchtech concludes treatment in head lice drug Phase 2b trial Pharmaceutical Business Review The trial involves around 132 healthy subjects with head lice infestation, 2 years of age and older, in two study centers in the US. DeOvo, a topical formulation of a known metalloprotease inhibitor, has shown both ovicidal and lousicidal activity and ... Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation ... |